Extracorporeal membrane oxygenation for acute respiratory distress syndrome in adults: an analysis of differences between survivors and non-survivors
Standard
Extracorporeal membrane oxygenation for acute respiratory distress syndrome in adults: an analysis of differences between survivors and non-survivors. / Panholzer, Bernd; Meckelburg, Katrin; Huenges, Katharina; Hoffmann, Grischa; von der Brelie, Michael; Haake, Nils; Pilarczyk, Kevin; Cremer, Jochen; Haneya, Assad.
In: PERFUSION-UK, Vol. 32, No. 6, 09.2017, p. 495-500.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Extracorporeal membrane oxygenation for acute respiratory distress syndrome in adults: an analysis of differences between survivors and non-survivors
AU - Panholzer, Bernd
AU - Meckelburg, Katrin
AU - Huenges, Katharina
AU - Hoffmann, Grischa
AU - von der Brelie, Michael
AU - Haake, Nils
AU - Pilarczyk, Kevin
AU - Cremer, Jochen
AU - Haneya, Assad
PY - 2017/9
Y1 - 2017/9
N2 - OBJECTIVES: Over the last decade, extracorporeal membrane oxygenation (ECMO) has become a promising option for patients with severe acute respiratory distress syndrome (ARDS). In this single-center observational cohort study, data from a patient group with severe ARDS treated with ECMO was analyzed.METHODS: Data from 46 patients [median age 54 years (18 to 72), male: 65.2%] were evaluated retrospectively between January 2009 and September 2015.RESULTS: Diagnosis leading to ARDS was pneumonia in 63.1% of the patients. The median SOFA Score was 13 (10 to 19) and the median LIS was 3.5 (2.67 to 4). The median duration of ECMO support was 12 days (1 to 86). Twenty-eight patients (60.9%) were successfully weaned from ECMO and 22 patients survived (47.8%). Non-survivors needed significantly more frequent renal replacement therapy (37.5% vs. 18.2%; p<0.01) and transfusion of red blood cell concentrates [0.4 units (0.3 to 1.2) vs. 0.9 units (0.5 to 1.6); p<0.01] during ECMO support compared to patients who survived.CONCLUSION: This report suggests that ECMO currently allows treatment of severe ARDS with presumed improved survival. The incidence rate of acute kidney injury and transfusion are associated with adverse outcomes.
AB - OBJECTIVES: Over the last decade, extracorporeal membrane oxygenation (ECMO) has become a promising option for patients with severe acute respiratory distress syndrome (ARDS). In this single-center observational cohort study, data from a patient group with severe ARDS treated with ECMO was analyzed.METHODS: Data from 46 patients [median age 54 years (18 to 72), male: 65.2%] were evaluated retrospectively between January 2009 and September 2015.RESULTS: Diagnosis leading to ARDS was pneumonia in 63.1% of the patients. The median SOFA Score was 13 (10 to 19) and the median LIS was 3.5 (2.67 to 4). The median duration of ECMO support was 12 days (1 to 86). Twenty-eight patients (60.9%) were successfully weaned from ECMO and 22 patients survived (47.8%). Non-survivors needed significantly more frequent renal replacement therapy (37.5% vs. 18.2%; p<0.01) and transfusion of red blood cell concentrates [0.4 units (0.3 to 1.2) vs. 0.9 units (0.5 to 1.6); p<0.01] during ECMO support compared to patients who survived.CONCLUSION: This report suggests that ECMO currently allows treatment of severe ARDS with presumed improved survival. The incidence rate of acute kidney injury and transfusion are associated with adverse outcomes.
KW - Acute Disease
KW - Adolescent
KW - Adult
KW - Aged
KW - Cohort Studies
KW - Extracorporeal Membrane Oxygenation/methods
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Respiratory Distress Syndrome/mortality
KW - Retrospective Studies
KW - Survival Analysis
KW - Young Adult
U2 - 10.1177/0267659117693075
DO - 10.1177/0267659117693075
M3 - SCORING: Journal article
C2 - 28820028
VL - 32
SP - 495
EP - 500
JO - PERFUSION-UK
JF - PERFUSION-UK
SN - 0267-6591
IS - 6
ER -
